|
AU2013205399A1
|
|
Methods and compositions for use in treatment of patients with autoantibody positive diseases
|
|
JP2013066468A
|
|
HUMAN ENDOKINE α
|
|
CN104039825A
|
|
Viral clearance methods
|
|
JP2012044999A
|
|
NEUTROKINE α
|
|
EP2582392A2
|
|
Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
|
|
JP2010279364A
|
|
207 human secreted proteins
|
|
US2011014190A1
|
|
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
WO2009102473A2
|
|
Human g-protein chemokine receptor (ccr5) hdgnr10
|
|
JP2009136294A
|
|
NEUTROKINE alpha
|
|
JP2009100747A
|
|
TRANSFORMING GROWTH FACTOR alphaHII
|
|
JP2009077723A
|
|
HUMAN ENDOKINE alpha
|
|
US2011105726A1
|
|
Antibodies to HSDEK49 polypeptides
|
|
AU2008201411A1
|
|
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
AU2008201237A1
|
|
Antibodies that Immunospecifically Bind to Trail Receptors
|
|
JP2008194038A
|
|
HUMAN TUMOR NECROSIS FACTOR delta and epsilon
|
|
US2009226429A1
|
|
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
|
US2008248046A1
|
|
Death domain containing receptor 5
|
|
WO2008140483A2
|
|
Methods and antibodies for detecting protective antigen
|
|
US2008194481A1
|
|
Albumin Fusion Proteins
|
|
US2008167238A1
|
|
Albumin Fusion Proteins
|
